GlassScriptPhysician profile
Marc Hirschbein
NPI 1447293519
$845.28
in general payments reported to CMS, 2019-2025
11 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.27 · 2020: $19.41 · 2021: $197 · 2022: $196 · 2023: $248 · 2024: $26.52 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $508.13 | 2019-2023 | Tepezza |
| Amgen INC. | $120.57 | 2024-2025 | Tepezza |
| Depuy Synthes Sales INC. | $50.57 | 2022 | |
| Dompe US, INC. | $32.94 | 2025 | Oxervate |
| Merz Pharmaceuticals, LLC | $26.83 | 2023 | Xeomin |
| Abbvie INC. | $24.24 | 2022 | |
| Bausch & Lomb Americas INC. | $19.96 | 2023 | Vyzulta |
| Allergan, INC. | $17.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.50 | 2021 | |
| Galderma Laboratories, L.P. | $13.91 | 2019 | |
| Genentech USA, INC. | $12.77 | 2023 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Hirschbein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.